Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTX NASDAQ:ENTX NASDAQ:IZTC NASDAQ:LGVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.79$1.95$1.28▼$9.50$60.20M1.6892,470 shs21,270 shsENTXEntera Bio$1.24$1.20$0.91▼$3.22$61.04M1.54107,743 shs26,040 shsIZTCInvizyne Technologies$9.92+5.5%$9.33$8.50▼$23.00$62.02MN/A37,647 shs17,598 shsLGVNLongeveron$0.82$0.94$0.48▼$1.80$19.08M-0.31410,109 shs351,679 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics0.00%+5.29%+29.71%-36.07%-65.84%ENTXEntera Bio0.00%+0.81%+10.71%-21.52%-36.41%IZTCInvizyne Technologies0.00%+1.64%-3.78%+11.46%-33.42%LGVNLongeveron0.00%+21.31%-12.74%+41.10%-39.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.79$1.95$1.28▼$9.50$60.20M1.6892,470 shs21,270 shsENTXEntera Bio$1.24$1.20$0.91▼$3.22$61.04M1.54107,743 shs26,040 shsIZTCInvizyne Technologies$9.92+5.5%$9.33$8.50▼$23.00$62.02MN/A37,647 shs17,598 shsLGVNLongeveron$0.82$0.94$0.48▼$1.80$19.08M-0.31410,109 shs351,679 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics0.00%+5.29%+29.71%-36.07%-65.84%ENTXEntera Bio0.00%+0.81%+10.71%-21.52%-36.41%IZTCInvizyne Technologies0.00%+1.64%-3.78%+11.46%-33.42%LGVNLongeveron0.00%+21.31%-12.74%+41.10%-39.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 2.00Hold$12.00570.39% UpsideENTXEntera Bio 2.00Hold$9.00625.81% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ALGVNLongeveron 2.25Hold$5.50570.57% UpsideCurrent Analyst Ratings BreakdownLatest LGVN, ENTX, DWTX, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/11/2026LGVNLongeveron Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/27/2026DWTXDogwood Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A$2.40 per shareN/AENTXEntera Bio$40K1,525.82N/AN/A$0.22 per share5.64IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ALGVNLongeveron$1.20M15.91N/AN/A$0.69 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$34.26M-$10.60N/AN/AN/AN/A-108.57%-30.28%8/12/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%N/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ALGVNLongeveron-$22.70M-$1.13N/AN/AN/A-1,844.49%-202.41%-140.67%8/12/2026 (Estimated)Latest LGVN, ENTX, DWTX, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DWTXDogwood Therapeutics-$0.22-$0.15+$0.07-$0.15N/AN/A5/13/2026Q1 2026LGVNLongeveron-$0.19-$0.19N/A-$0.19$0.33 million$0.40 million5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/18/2026Q4 2025DWTXDogwood Therapeutics-$1.22-$0.26+$0.96-$0.26N/AN/A3/17/2026Q4 2025LGVNLongeveron-$0.42-$0.22+$0.20-$0.22$0.11 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A5.862.76ENTXEntera BioN/A7.937.93IZTCInvizyne TechnologiesN/AN/AN/ALGVNLongeveron0.053.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%ENTXEntera Bio14.11%IZTCInvizyne TechnologiesN/ALGVNLongeveron10.01%Insider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics0.20%ENTXEntera Bio10.38%IZTCInvizyne TechnologiesN/ALGVNLongeveron11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics533.63 million33.56 millionN/AENTXEntera Bio2049.22 million44.12 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/ALGVNLongeveron2023.27 million20.66 millionNot OptionableLGVN, ENTX, DWTX, and IZTC HeadlinesRecent News About These CompaniesLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesMay 20, 2026 | globenewswire.comReviewing Longeveron (NASDAQ:LGVN) & CorMedix (NASDAQ:CRMD)May 15, 2026 | americanbankingnews.comLongeveron Earnings Call: Trial Milestones Amid FDA HurdlesMay 14, 2026 | tipranks.comLGVN Set for Success in 2026May 14, 2026 | finance.yahoo.comLongeveron (LGVN) Q1 2026 Earnings TranscriptMay 14, 2026 | fool.comLongeveron Inc. (LGVN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateMay 13, 2026 | globenewswire.comMaxim Group downgrades Longeveron (LGVN)May 12, 2026 | msn.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart ...May 11, 2026 | markets.businessinsider.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)May 11, 2026 | globenewswire.comLGVN stock slips after hours as FDA flags concerns on rare heart defect trial designMay 10, 2026 | msn.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart ...May 10, 2026 | markets.businessinsider.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)May 8, 2026 | globenewswire.comLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026May 5, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)April 16, 2026 | theglobeandmail.comLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)April 8, 2026 | globenewswire.comLongeveron Receives Extended Nasdaq Compliance Grace PeriodMarch 25, 2026 | tipranks.comLongeveron Cancels Special Meeting, Reschedules Reverse Split VoteMarch 24, 2026 | tipranks.comLongeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | insidermonkey.comLongeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline PressureMarch 19, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGVN, ENTX, DWTX, and IZTC Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$1.79 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.66 -0.13 (-7.26%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Entera Bio NASDAQ:ENTX$1.24 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.24 0.00 (-0.40%) As of 05/22/2026 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Invizyne Technologies NASDAQ:IZTC$9.92 +0.52 (+5.53%) As of 05/22/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Longeveron NASDAQ:LGVN$0.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.84 +0.02 (+3.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
